VP, DMD Commercial Asset Lead

Overview

Our commitment to people with neuromuscular diseases

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more, and follow us on X, Linked In and Facebook.

The VP, DMD Commercial Asset Lead (CAL) is a passionate driver for maximizing the value of Dyne’s DMD commercial assets with a global perspective, who brings adaptable leadership to develop and implement commercialization strategies to maximize the reach and value creation of Dyne’s DMD commercial assets in the neuromuscular portfolio. This mandate includes market analysis, competitive positioning, launch readiness and execution and input into lifecycle management in the relentless pursuit of long-term success in bringing the asset to patients globally.

The CAL is a highly visible leadership role. As a key member of an experienced Program Team, the CAL will work with the cross-functional team to influence and shape the Program strategy. The CAL leads all efforts in defining the commercialization strategy, strategic imperatives, critical success factors, executional priorities, and launch efforts together with the launch teams of the affiliates, bringing both a ‘future-orientation’ toward the goal of broad, global access for patients in need, and a “pragmatic-orientation” to chart the path, mitigate risks, cultivate options.

The CAL collaborates with program team, functional leads and affiliate teams to achieve a differentiated product profile, competitive label, broad reimbursement and highly successful launches globally starting with the US launch.

The CAL, as a member of the program team, is responsible for securing commercialization and works hand in hand in strong partnership with the Program Lead, the Head of Commercialization, all functional leaders and the affiliate launch teams.

This role is based onsite in Waltham, MA.

• Define global asset commercialization strategy and plan to achieve milestones and timelines for successful launches
• As a key member of the Program Team and Head of DMD Commercial Sub Team, ensure that all key pillars for successful commercialization for the assets are secured – starting with differentiation in endpoints to achieve a competitive product profile/label, regulatory strategy, filing strategy, with value & access to secure the value proposition for the assets and achieve reimbursement in US and at the right time globally, partner with supply, medical, marketing, digital and the data team to prepare successful launch strategy and execution for all key markets starting with US.
• Provide input and expertise to a robust and well-understood program strategy with the key objective of gaining the approvals of potentially life-changing medicines for patients around the world to generate value for patients and shareholders and maximize topline growth.
• Structure and facilitate critical cross-functional decisions on commercialization aspects of the asset within Program Teams and senior leadership teams, bringing all relevant perspectives to bear while driving to efficient decisions in a fast-paced environment.
• Working with cross-functional launch team in key markets, starting with the US team, and Strategic Commercial Partners to secure reimbursement and successful launches, by propelling successful launch execution from one country to the other.
• In close collaboration with the Program Lead and Head of Commercialization, consider and advocate for the needs of the commercial asset in the context of Dyne’s corporate strategy and priorities.
• Drive preparation and presentation of materials for Board of Directors on asset commercialization topics
• Maintain…